Description
This blend combines Cagrilintide, a long-acting amylin analog, with a GLP-1 receptor agonist peptide, bringing two complementary metabolic signaling pathways into a single research preparation. It is used to study amylin and incretin activity in parallel.
Non-clinical studies in cell systems and animal models have examined satiety signaling, glucose regulation, gastric-emptying pathways, and dual receptor engagement. The combined format supports comparative research into how amylin and GLP-1 signaling interact.
Intended use: In vitro and preclinical in vivo laboratory research only. Not approved for human or veterinary use.
Reviews
There are no reviews yet.